The optimal immune globulin replacement dosages required over time to minimize infection risks in patients with Primary Antibody Deficiencies are not definitely established. As with many interventions, there may be specific subgroups of patients who are more likely to benefit from treatment with higher or lower dosages. The aim of the study was to verify the efficacy of a rationale for individualized immune globulin utilization and to elucidate the effects of care on patient outcome.
|Numero di pagine||7|
|Rivista||Journal of Clinical Immunology|
|Stato di pubblicazione||Pubblicato - 2014|
- Primary antibody deficiencies